HP
48
3
EL
25
4
SEE
56
6
GT
62
6
DG
6
2
NDAQ
62
2
EMN
60
4
VZ
50
3
EFX
38
2
CTSH
56
2
ADT
53
3
TSCO
49
5
SYK
64
-4
NAVI
52
5
BAC
53
3
RHI
59
2
HCP
66
8
BA
54
5
PYPL
54
2
UA
50
-9
HP
48
3
EL
25
4
SEE
56
6
GT
62
6
DG
6
2
NDAQ
62
2
EMN
60
4
VZ
50
3
EFX
38
2
CTSH
56
2
ADT
53
3
TSCO
49
5
SYK
64
-4
NAVI
52
5
BAC
53
3
RHI
59
2
HCP
66
8
BA
54
5
PYPL
54
2
UA
50
-9
Financhill
Back

Viking Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
38

VKTX
Viking Therapeutics

Last Price:
52.62
Seasonality Move:
50.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Viking Therapeutics Price Quote

$52.62
+0.03 (+1.92%)
(Updated: November 23, 2024 at 5:59 AM ET)

Viking Therapeutics Key Stats

Sell
38
Viking Therapeutics (VKTX) is a Sell
Day range:
$51.95 - $53.52
52-week range:
$11.55 - $99.41
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.43%
Volume:
2.6M
Avg. volume:
5.5M
1-year change:
354.93%
Market cap:
$5.9B
Revenue:
$0
EPS:
$-0.93

How Much Does Viking Therapeutics Make?

Data Unavailable

Is Viking Therapeutics Growing As A Company?

Data Unavailable

Viking Therapeutics Stock Price Performance

What Is Viking Therapeutics 52-Week High & Low?

Viking Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Viking Therapeutics?

Is Viking Therapeutics Cash Flow Positive?

  • What Is VKTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$74.2M
  • What Is Viking Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $611.7M
  • What Is Viking Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$524.2M

Viking Therapeutics Return On Invested Capital

Data Unavailable

Viking Therapeutics Earnings Date & Stock Price

Viking Therapeutics Competitors

Viking Therapeutics Dividend Yield

Viking Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.12%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 112.57
Upside from Last Price: 114.05%

Major Shareholders

  • How many VKTX shares are owned by institutional investors?
    163.4M VKTX shares are owned by institutional investors
  • How many VKTX shares are owned by insiders?
    4.3M VKTX shares are owned by insiders